To clarify the association between PCSK9 (proprotein convertase subtilisin/kexin type 9) and Lp(a) (lipoprotein [a]), we studied Lp(a) kinetics in patients with loss-of-function and gain-of-function PCSK9 mutations and in patients in whom extended-release niacin reduced Lp(a) and PCSK9 concentrations.
L p(a) (lipoprotein [a]) consists of one molecule of apo(a) (apolipoprotein [a]) bound covalently to the apoB100 (apolipoprotein B100) of a LDL (low-density lipoprotein)-like particle. An elevated plasma Lp(a) concentration is regarded as a strong cardiovascular risk factor. 1, 2 However, metabolic pathways governing Lp(a) concentrations remain poorly understood.
The LDL receptor (LDLR) was first proposed as a potential route for Lp(a) catabolism, as individuals with familial hypercholesterolemia (FH) and LDLR mutations display higher plasma Lp(a) concentrations. 3 The inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9), a circulating endogenous inhibitor of the LDLR, provided data supporting this hypothesis. PCSK9 inhibitors restored LDLR expression at hepatocyte surfaces, thereby markedly reducing LDL-cholesterol (LDL-C) concentrations. 4, 5 In parallel, PCSK9 inhibitors generated an unexpected 20% to 30% reduction in plasma Lp(a) concentrations, proportional to the treatment dose and the baseline level of plasma Lp(a). 6 PCSK9 inhibition with monoclonal antibodies (ie, alirocumab and evolocumab) or small interfering RNA (ie, inclisiran) similarly reduces Lp(a) plasma levels, albeit through different mechanisms of action. 7, 8 However, unlike LDL-C reduction, widely varying responses were observed among individuals in whom Lp(a) was reduced, with no clear relationship with the apo(a) polymorphic size, or the baseline PCSK9 plasma concentration. [9] [10] [11] Statins also increase LDLR expression but, in contrast to PCSK9 inhibitors, they have no effect on or only slightly increase the plasma Lp(a) concentration. 12 Controversial in-vitro results have been also reported regarding the mechanism of action of Lp(a) reduction with PCSK9 inhibitors, ranging from a key role of the LDLR in Lp(a) catabolism 13 to a key role of PCSK9 in Lp(a) production. 14 In humans, Lp(a) fractional catabolic rates (FCR) were found to be similar in patients with FH and controls. 15 In nonhuman primates, we reported that alirocumab strongly reduced the circulating Lp(a) concentration by acting on apo(a) production rate. 16 In humans, in vivo lipoprotein kinetics studies with PCSK9 monoclonal antibodies have also led to conflicting data. While alirocumab induced a nonsignificant increase in the Lp(a) FCR in one study, 17 evolocumab led to a significant decrease in the Lp(a) production rate in another one. 18 However, since the combination of evolocumab with atorvastatin increased Lp(a) FCR, the role of an overexpressed LDLR at the hepatocyte surface in Lp(a) catabolism could be probable.
The apo(a) size, defined as the number of Kringle IV-2 copies on the LPA gene, governs 30% to 70% of circulating Lp(a) levels. 19 Recent studies showed that the APOE and PCSK9 genes may also influence Lp(a) levels. 20, 21 We showed that single-nucleotide polymorphisms of apoE (apolipoprotein E), a ligand for the LDLR and the LRP-1 (LDLR-related protein), influence plasma Lp(a) concentrations in patients with FH with LDLR mutations. 22 However, the underlying mechanisms remain unknown.
To gain further insight into mechanisms governing Lp(a) concentrations, we studied patients carrying rare loss-of-function (LOF) and gain-of-function (GOF) mutations of PCSK9. 23, 24 We previously showed that PCSK9 mutations strongly modulate LDL catabolic rates, independently of any pharmacological inhibitor. 24, 25 In the present study, we aimed to extend this research by analyzing Lp(a) kinetics in these patients and their relationships with plasma PCSK9 and other lipoprotein components. We also compared our results with those obtained in an interventional study examining the ability of extended-release niacin (ERN) to reduce LDL-C, PCSK9, and Lp(a) concentrations. 26 
MATERIALS AND METHODS
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Patients and Controls
Lp(a) kinetics were explored in patients with various phenotypes: 3 subjects with the dominant-negative heterozygous fractional catabolic rates were similar between patients displaying loss-or a gain-of-function PCSK9 mutations. • VLDL (very-low-density lipoprotein)-apoE (apolipoprotein E) absolute production rates were positively correlated with Lp(a)-apo(a) absolute production rate. • Proteomic analysis of isolated Lp(a) particles showed that the apoE content of Lp(a) increased significantly with plasma Lp(a) but not with PCSK9 concentration. • Under extended-release niacin-induced reductions of Lp(a), PCSK9, and VLDL-apoE concentrations, the relative changes in the VLDL-apoE and Lp(a)apo(a) absolute production rates were strongly correlated, whereas changes in plasma PCSK9 concentration correlated only with changes in VLDL-apoE absolute production rate.
Nonstandard Abbreviations and Acronyms
R104C/V114A PCSK9 LOF mutation (PCSK9-LOF group); 24 and 9 patients with FH, consisting of 4 heterozygous PCSK9 GOF mutation carriers (3 with S127R, 1 with R218S; PCSK9-GOF group), 25 and 5 controls with FH and heterozygous LDLR mutations (FH-LDLR group). 27 The control (CTL) group was composed of 6 healthy volunteers. 28 The clinical characteristics of the patients are detailed in Table 1 . The Ethics Committee of Nantes approved the clinical protocol, and written informed consent was obtained from all subjects (protocol referenced as no. 15/06-BRD 06/3-E).
ERN Intervention
We supported our study findings by performing additional analyses of data from a previously reported intervention trial. 26 Eight nondiabetic overweight male subjects ( Table 1) were enrolled in a randomized crossover controlled study (8 weeks/ phase and a 4-week washout interval) comparing the effects of placebo and 2 g/day ERN. In that study, ERN resulted in the reduction of plasma Lp(a) and PCSK9 concentrations. 26 The Ethics Committee of Nantes approved the clinical protocol (trial no. NCT01216956), and written informed consent was obtained from all subjects.
Kinetic Protocol
After an overnight fast, each subject received a bolus of 10 µmole/kg 2H 3 were separated by sequential ultracentrifugation. 25 Samples were stored at −80°C until use.
Biochemical Measurements
Cholesterol and triglyceride (TG) concentrations were measured using enzymatic kits from Boehringer Mannheim GmbH (Mannheim, Germany). Plasma PCSK9 and Lp(a) concentrations were measured by ELISA (R&D Systems, Lille, France and Aviva Systems Biology Corporation, CA). 
CLINICAL AND POPULATION STUDIES -AL

Plasma Leucine Measurements
Plasma leucine (endogenous leucine and exogenous 2H 3leucine) concentrations were measured by electron-impact gas chromatography-mass spectrometry as described previously. 25 Briefly, amino acids were purified by cation exchange chromatography and then derivatized by heptafluorobutyric acid. The isotopic ratio was determined by selected ion monitoring at mass-to-charge ratios of 282 (leucine) and 285 ( 2 H 3 -leucine).
Lp(a) Immunoprecipitation
Lp(a) was immunoprecipitated from plasma samples (50 µL) using the precoated wells of an Lp(a) ELISA kit (Aviva Systems Biology Corporation, monoclonal antibody). After the performance of blocking procedures according to the supplier's instructions, the wells were washed and trypsin digested for mass-spectrometry analyses.
Apolipoprotein Quantification
Apolipoproteins were quantified in plasma and lipoprotein fractions using trypsin proteolysis and subsequent analysis of proteotypic peptides by liquid chromatography-tandem mass spectrometry as described previously. 26, 29, 30 Quantification was performed with 3 replicates at all kinetic time points. Apo(a) polymorphic sizes were determined using 2 proteolytic peptides, 26 and apoE phenotypes were determined using a combination of 5 proteolytic peptides. 30 The intra-and inter-assay variabilities did not exceed 7.1%.
Apolipoprotein Enrichment Measurement
The isolation and measurement of leucine enrichment in apoB100 were performed as described previously. 25 Briefly, apoB100-containing lipoprotein fractions (VLDL, IDL, LDL) were isolated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then hydrolyzed with concentrated hydrochloric acid solution. Amino acids were purified by cation exchange chromatography, derivatized (with heptafluorobutyric acid), and analyzed by gas chromatography-mass spectrometry as described above. VLDL-apoE and Lp(a)-apo(a) leucine enrichments were measured in concentrated lipoprotein fractions by liquid chromatography-tandem mass spectrometry, as detailed previously. 26, 29 As the majority (≈95%) of Lp(a) particles are located in the density range of 1.019 to 1.210 g/mL following ultracentrifugation of plasma samples, equal volumes of ultracentrifuged fractions of LDL (1.019-1.063 g/mL), and HDL (1.063-1.21 g/mL) were combined. Leucine enrichment measurements were performed on 3 replicates at all kinetic time points, and the intra-and inter-assay variabilities did not exceed 6.8%.
Modeling
Lp(a)-apo(a) and VLDL-apoE FCRs were estimated using the SAAM II modeling program (Epsilon Group, Charlottesville, VA) and by fitting of a mono-compartmental model. 26, 29 Kinetic data for VLDL-and LDL-apoB100 were calculated using a multiple compartmental model including IDL-apoB100 enrichment measurements, as described previously. 25 Due to the heterogeneity of patients' lipid profiles, the asymptotic plasma leucine plateau (tracer-to-tracee ratio) was used as a pool precursor, instead of the VLDL-apoB100 asymptotic plateau. Pool sizes were considered to be constant, as no significant variation was observed in apolipoprotein concentrations at different sampling times (concentration variations within 8.2%). At this steady state, the FCR was equal to the fractional synthetic rate. Therefore, absolute production rates (APRs) were calculated as the products of the FCR and the pool sizes of apolipoproteins in lipoprotein fractions, and assuming a plasma volume of 4.5% of body weight.
Statistical Analysis
Results are expressed as mean±SDs, unless otherwise specified. Statistical analyses were performed with GraphPad Prism software (version 6.0; GraphPad Software, Inc, La Jolla, CA 
RESULTS
Biochemical Findings
Baseline lipid parameters of the patients are provided in Table 2 . As expected, patients in the PCSK9-LOF group displayed dramatically reduced plasma total cholesterol, LDL-C, and PCSK9 concentrations compared with the other groups. Plasma concentrations of apoB100 and apoE were also reduced in these patients. In contrast, LDL-C and plasma apoB100 concentrations were increased in the PCSK9-GOF and FH-LDLR groups, associated with a trend of higher plasma apoE concentrations. Plasma Lp(a) and apo(a) concentrations were significantly correlated (r=0.60; P=0.009). Plasma Lp(a) concentrations were increased in patients with PCSK9-GOF and LDLR mutations (14.0±12.1 mg/dL, n=9) compared with the others (5.3±3.6 mg/dL, n=9; P=0.039). Analysis of lipoprotein apolipoprotein content showed reduced concentrations of apoB100 and apoE in the VLDL and LDL fractions in the PCSK9-LOF group (Tables I and II in the online-only Data Supplement). After specific immunoprecipitation of Lp(a) particles, apo(a) concentrations were close to the sum of recovery in the VLDL, LDL, and HDL fractions. In isolated Lp(a) particles, the apoB100-to-apo(a) molar ratio was close to 1, excluding possible contaminations with other apoB-containing lipoproteins, whereas the apoEto-apo(a) molar ratio ranged from 0.5 to 3 and correlated with plasma Lp(a) concentrations (r=0.96, P<0.0001; 
Kinetics of Lp(a) and Other Apolipoproteins
The asymptotic plasma leucine plateaus used as precursor pools were of 10.1±0.2% (PCSK9-LOF), 11.0±1.2% (PCSK9-GOF), 10.4±0.5 % (FH-LDLR), and 8.6±0.5% (CTL). The reduced precursor pool of CTL patients could explain the marked difference in VLDL-apoB100 asymptotic plateaus between CTL and PCSK9-LOF patients (Figure 2A ). But the opposite was observed for VLDL-apoE. This could stem from the sharply distinct lipid profiles of those patients. Since CTL individuals displayed elevated plasma TG and reduced HDL-C ( Table 2) compared with PCSK9-LOF subjects, apoE could for instance be differently exchanged between VLDL and HDL particles in such patients. Lp(a)-apo(a) FCR were similar in all groups (Figure 2 ). The APR of Lp(a)-apo(a) was within the same lower range in the CTL and PCSK9-LOF groups and was slightly increased in the FH-LDLR and PCSK9-GOF groups. The VLDL-apoE FCR was lower in the FH-LDLR and PCSK9-GOF groups and was slightly decreased in the PCSK9-LOF group compared with the CTL group. The VLDL-apoE APR was within the same range in the CTL, PCSK9-GOF, and FH-LDLR groups and decreased in the PCSK9-LOF group. The VLDL-and LDL-apoB100 FCRs were dramatically increased in the PCSK9-LOF group, and the LDL-apoB100 FCR was decreased in the FH-LDLR and PCSK9-GOF groups. Of note, plasma PCSK9 concentrations correlated negatively with the VLDL-apoB100 (r=-0.57; P=0.015) and LDL-apoB100 (r=-0.47; P=0.049) FCRs, but not with their APRs. Unfortunately, we were not able to detect Lp(a)-apoB100 and Lp(a)-apoE enrichments in isolated Lp(a) particles because of liquid chromatography-tandem mass spectrometry limits of detection. Due to this methodological limitation, we were not able to develop a multicompartmental model to evaluate the kinetics of Lp(a) components (apoB100, apo(a) and apoE).
Parameters Governing Lp(a) Kinetics
Lp(a)-apo(a) concentrations and APR were strongly and negatively correlated with the mean repeats of Kringle IV (r=-0.64, P=0.004 and r=-0.71, P<0.001, respectively; Table 3 ). No significant correlation was found between Lp(a)-apo(a) kinetic parameters and plasma PCSK9 concentrations or VLDL-or LDL-apoB100 kinetics. The main finding was the significant correlations observed between Lp(a)-apo(a) and VLDL-apoE kinetics parameters. Total apoE and VLDL apoE concentrations and VLDL-apoE APR correlated positively with Lp(a)-apo(a) concentrations and APR (Table 3) but not with the Lp(a)-apo(a) FCR. The VLDL-apoE FCR correlated with the Lp(a)-apo(a) FCR. No significant correlation was found between the plasma PCSK9 concentration and any concentration or kinetics parameters of apoE. Additional correlations between apoB100, apoE, and apo(a) kinetic parameters are shown in Table  III in the online-only Data Supplement. As expected, VLDL-apoE was significantly correlated with plasma TG (r=0.59; P=0.009) and VLDL-apoB100 (r=0.73; P=0.001). Only a nonsignificant trend was found for the correlation between VLDL-apoB100 and Lp(a)apo(a) (r=0.45; P=0.063).
Modulation of Lp(a), apoE, and PCSK9 With ERN
To further evaluate the association between Lp(a)-apo(a) and VLDL-apoE APRs, we studied the effects of ERN on the lipoprotein kinetics of patients with mild hypertriglyceridemia. As reported previously and summarized in Table  IV in the online-only Data Supplement, ERN improved the lipid profile by reducing Lp(a)-apo(a) by 20% (P=0.008), apoB100 by 21% (P=0.008), TG by 44% (P=0.023), and LDL-C by 16% (P=0.039). ERN also increased HDL-C by 22% (P=0.008). Plasma PCSK9 and VLDL-apoE concentrations were also reduced with ERN by 35% (P=0.008) and 42% (P=0.008), respectively, whereas no significant change was observed in total apoE concentrations. We previously showed that the ERN-induced reduction of Lp(a)-apo(a) concentrations was related to a balance between a 50% reduction in the Lp(a)-apo(a) APR and a 37% reduction in the Lp(a)-apo(a) FCR. In contrast, we observed that the decrease in VLDL-apoE concentrations was related to the reduction of its APR by 47% (P=0.008; Figure 3A ). Additional correlations between changes related to ERN are shown in Table V in the online-only Data Supplement and Figure 3B . Interestingly, changes in the VLDL-apoE APR correlated with changes in the Lp(a)-apo(a) APR (r=0.83; P=0.015) and plasma PCSK9 concentration (r=0.79; P=0.028). A nonsignificant trend for a positive correlation between changes in the Lp(a)-apo(a) APR and plasma PCSK9 concentration (r=0.69; P=0.070) was also noted (Figure 3B ). Of note, in isolated Lp(a) particles, the apoE-toapo(a) molar ratio was still correlated with plasma Lp(a) concentrations (r=0.82; P=0.0132, Figure I in the onlineonly Data Supplement). Again, no significant correlation was found between Lp(a) concentrations and the apoEto-apoB100 ratios calculated in VLDL/LDL particles.
Multivariate Analysis Findings
To further assess and confirm the determinants of apo(a)/Lp(a) concentrations, we performed multivariate analyses of the lipid and lipoprotein parameters of all studied patients. Principal component analysis clearly identified all groups ( Figure 4A ) and explained 55% of the variance in apo(a) concentrations. The correlation cluster identified variables associated positively with apo(a), including age, TG, VLDL-apoB100, plasma apoE, and PCSK9, whereas apo(a) Kringle IV repeats were strongly and negatively correlated. Importantly, the correlation network clearly associated VLDL-apoE concentrations and APR as main determinants of plasma apo(a) concentrations ( Figure 4B ).
DISCUSSION
We showed that plasma Lp(a) concentrations were slightly increased in patients with FH with LDLR or PCSK9-GOF mutations compared with healthy subjects and those with PCSK9 LOF mutations, but no significant effect was observed on the Lp(a)-apo(a) production and catabolic rates. We also showed a reduction in plasma apoE concentration in patients with PCSK9 LOF mutation, related mainly to a decrease in its APR into VLDL. Interestingly, VLDL-apoE APR was positively correlated with Lp(a)-apo(a) APR. In addition, the specific analysis of Lp(a) particles revealed that the apoE-to-apo(a) molar ratio increased significantly with plasma Lp(a), but not PCSK9, concentration. Under ERN-induced reductions of Lp(a), PCSK9 and VLDL-apoE concentrations, the relative changes in the VLDL-apoE and Lp(a)-apo(a) APRs were strongly correlated, whereas changes in plasma PCSK9 concentration correlated only with changes in VLDL-apoE APR.
This finding is somewhat unexpected as patients with type 2 diabetes mellitus often exhibit elevated TG concentrations, attributed to an overproduction and a reduced clearance of triglyceride-rich lipoproteins, 31 and reduced Lp(a) concentrations. 32 In addition, other studies showed a negative association between Lp(a) and TG plasma levels 33 and between plasma Lp(a) and extralarge, large, and medium-sized VLDL particles. 34 Another study reported a delayed catabolism of a portion of Lp(a) in a homozygous apoE-deficient subject, resulting in elevated Lp(a) plasma concentration. 35 However, this work aimed to clarify the relationship between PCSK9 and Lp(a) metabolisms, as PCSK9 inhibitors reduce plasma Lp(a) levels. 36 To achieve this goal, we included patients with rare PCSK9 LOF and GOF mutations. The patients with PCSK9 LOF mutations originated from the same family and carried the same mutation (R104C/V114A). Patients with heterozygous PCSK9 GOF mutations came from 2 families with different mutations (S127R and R218S) but displayed homogenous kinetic parameters. As reported previously, VLDL-and LDL-apoB100 FCRs were strongly increased in the PCSK9-LOF group, and LDL-apoB100 FCR was decreased in the PCSK9-GOF group, similarly to those in patients with heterozygous FH-LDLR mutations. 24, 25 Despite strong differences in plasma PCSK9 concentrations or LDL-apoB100 FCR, Lp(a)-apo(a) FCR was similar in patients carrying PCSK9 LOF and GOF mutations. These results challenge the role for PCSK9 in Lp(a) catabolism, as observed previously with PCSK9 inhibitors in human hepatocytes in vitro 14 and in nonhuman primates or healthy volunteers in vivo. 16, 18 However, Lp(a)-apo(a) APR did not correlate with plasma PCSK9 concentrations, likely due to the small number of subjects.
Beyond Lp(a) levels, PCSK9 inhibitors also reduce plasma apoE concentrations. 17, 37 In this study, total plasma and VLDL apoE concentrations were lowered in the PCSK9-LOF group compared with the FH-LDLR and PCSK9-GOF groups. Interestingly, the Lp(a)-apo(a) APR was strongly correlated with total plasma and VLDL apoE concentrations and VLDL-apoE APR. As previous studies using PCSK9 inhibitors did not explore apoE kinetics, we gained further insights from additional analyses from an ERN study that previously showed reduction of plasma Lp(a) and PCSK9 concentrations. 26 Here, we showed that ERN strongly reduced the VLDL-apoE concentration as a consequence of a sharp reduction in its APR. The reduction in VLDL-apoE production was correlated with that of Lp(a)-apo(a), whereas the interaction with that of the plasma PCSK9 concentration was more puzzling. Therefore, apoE and especially VLDL-apoE may influence Lp(a) production, synthesis, or assembly, but the role of PCSK9 in this phenomenon remains to be determined. It could be related to similar modulations of production rates of VLDL carrying apoE and apo(a), as suggested by reduced VLDL-apoE and Lp(a)-apo(a) APRs in patients with PCSK9 LOF mutations. However, the VLDL-apoB100 APR did not differ in these patients compared with the others.
Lp(a) and apoE interactions have not been explored in depth, probably because Lp(a) synthesis and regulation are not clearly understood. 36 Whether Lp(a) assembly occurs in hepatocytes, at hepatocyte surfaces, or in the Disse space remains a matter of debate, but several kinetic studies suggested that a large part of Lp(a) assembly takes place outside of hepatocytes. 38, 39 Lp(a) synthesis requires the covalent binding of Kringle IV-9 of apo(a) [C4057] to apoB100 [C4326] by a disulfide bond. 30 However, the role of the native lipoprotein composition for final Lp(a) synthesis remains unclear. Proteomic analyses identified numerous proteins associated with Lp(a) beyond apo(a) and apoB100, such as apoA-I, apoC-I, apoC-II, apoC-III, and apoE. 40 In addition, correlation networks indicated strong interactions between apo(a), apoB100, and apoE. 40, 41 Hence, we can speculate that changes in apoE concentrations in Lp(a) precursors act on apo(a)-apoB100 binding. In support of this hypothesis, epidemiological studies demonstrated March 2020 827 differences in plasma Lp(a) concentrations between apoE genotypes based on the 3 major isoforms of human apoE (ε2/ε3/ε4). 29, 30, 34, 35 We also reported recently that apoE genotypes modulate plasma Lp(a) and apoE concentrations in patients with FH. 22, 30 Here, we showed that total and VLDL apoE concentrations correlated with apo(a) concentrations, irrespective of the apoE genotype, as all patients displayed the E3/E3 phenotype except one (E3/E4). Our observations suggest that apo(a) and therefore Lp(a) are modulated by apoE, with distinct mechanisms involving the apoE genotype and VLDL-apoE concentration. Interventional studies on plasma Lp(a) levels with different lipid-lowering drugs exhibiting various mechanisms of action (PCSK9 inhibitor, 18 apoB100 antisense oligonucleotide, 45 CETP inhibitor, 46, 47 ezetimibe, 48 fibrates, 48, 49 and statins 37, [49] [50] [51] ) also suggested that plasma Lp(a) reduction is associated with a decrease in the total or VLDL apoE concentration. A decrease in the Lp(a) production rate is the most frequently offered explanation for Lp(a) reduction, irrespective of treatment. In contrast, the mechanisms by which apoE is reduced are more puzzling and involve catabolic or production rates in HDL or VLDL. This uncertainty could be related to the use of different drugs or to the examination of patients with various lipid profiles or apoE genotypes. However, these studies have suggested that apoE concentrations are more critical than apoE kinetics and provide more evidence for the role of apoE in apo(a)-apoB100 binding and modulation. The effect of PCSK9 on Lp(a) could thus be related to its action on apoE metabolism. Changes in VLDL-apoE catabolism through the LDLR and LRP-1 are likely to occur with PCSK9 mutations or inhibitors and could explain the reduction in the plasma or VLDL apoE concentration and subsequent decrease in the plasma Lp(a) concentration.
This study has some limitations, such as the small numbers of subjects and PCSK9 mutations related to their low prevalence and to limited access to stable isotope kinetic studies in humans. In addition, only one patient exhibited plasma Lp(a) levels beyond the strong cardiovascular risk threshold of 125 nmol/L (ie, 50 mg/dL). Some methodological aspects have to be also acknowledged. Despite our efforts for isolating Lp(a) by immunoprecipitation, we were not able to detect 2 H 3 -leucine enrichments for Lp(a)-apoB100 and Lp(a)-apoE, which would be of interest for validating our hypothesis. Another hurdle, unrelated to the MS technology, is the exchange of apoE between lipoproteins and its possible shedding off of the lipoprotein surface by ultracentrifugation, which could lead to biases for the accurate determination of apoE pool sizes in lipoproteins. 30 Finally, several protocols can be employed for stable isotope kinetic studies such fasting versus fed states or bolus versus primed constant infusion of labeled tracer. 52 The primed constant infusion that we used here presents some disadvantages to estimate kinetics of apolipoproteins with relatively slower turnover rates such as that of Lp(a)-apo(a). Therefore, labeled tracers have tended to be administered as a bolus and the duration of the experimental protocols extended to 96 hours as previously described for Lp(a) kinetics. 53 Such differences in experimental protocols lead to contrasted kinetic parameters for Lp(a)-apo(a).
Hence, our study is observational and aimed to generate new hypotheses for Lp(a) metabolism. Our findings need to be investigated further with in vitro or in vivo experiments in patients with elevated Lp(a) plasma concentrations, and specific interventions involving VLDL-apoE modulation are mandatory to confirm the interaction between apoE and Lp(a) synthesis.
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